Sinew Pharma Inc.
Taipei Exchange 6634.TWO
Sinew Pharma Inc. Free Cash Flow Yield on January 14, 2025: -0.00%
-
Sinew Pharma Inc. 52-week high Free Cash Flow Yield is -0.00% on July 18, 2024, which is 50.00% above the current Free Cash Flow Yield.
-
Sinew Pharma Inc. 52-week low Free Cash Flow Yield is -0.00% on January 14, 2025, which is 0.00% below the current Free Cash Flow Yield.
-
Sinew Pharma Inc. average Free Cash Flow Yield for the last 52 weeks is -0.00%.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Dr. Kai-Min Chu M.D., Ph.D. |
| IPO Date | June 30, 2017 |
| Location | |
| Headquarters | C516, Building C |
| Employees | 51 |
| Sector | Health Care |
| Industries | |
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email